Year-end Sale % OFF 
Abstract
Positron Emission Tomography using 18F-fluoro-deoxi-glucose (FDG-PET) is giving a new perspective in disease staging and therapeutic response evaluation in daily oncological practice. To understand better the biological behavior and therapeutic response of breast cancer, new tracers and targets of molecular imaging are under investigation.These tracers may lead to non-invasive evaluation of the main, leading therapeutic decision-maker properties of metastatic breast cancer such as receptor status, proliferation activity and therapy resistance, and could also become predictive markers in the early measurement of therapeutic response in the neoadjuvant treatment of locally advanced breast cancer. However, these new agents are currently not available in the daily practice; the preliminary results are promising.
Highlights
In the western world breast cancer is the most common malignancy and cause of cancer death in women second only to lung cancer [1]
In our paper we review these new pathways of radiotracer researches in Positron Emission Tomography (PET)-imaging
Lubberink et al [66] in their structured study with dynamic FLT-PET imaging in locally advanced breast cancer patients treated with neoadjuvant chemotherapy, compared the effectiveness of tumor-to-whole blood ratio (TBR) measurements with the semi quantitative SUV
Summary
In the western world breast cancer is the most common malignancy and cause of cancer death in women second only to lung cancer [1]. The hybrid PET-CT imaging is a unique tool in the field of diagnostic imaging modalities: its main advantage is the ability to measure not just morphological, and metabolical properties and even biological behavior of the tissues These benefits increase the role of PET-CT diagnostics in oncology, especially in breast cancer diagnostics. It is possible to sample recurrent or metastatic tumors, in most cases sampling is troublesome or even impossible For these patients a specific estrogen imaging method could be determinative for the later therapy giving the chance to analyze the whole tumor tissue with one imaging technique, avoid sampling errors and unnecessary delay in the appropriate treatment of cancer patients [15]–these are the guiding light of present and future researches with hormone receptor imaging techniques
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
